Document Detail


Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries.
MedLine Citation:
PMID:  15557365     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Epidermal growth factor receptor (EGFR) transactivation is a mediator of angiotensin II (Ang II) signaling in cultured vascular smooth muscle cells isolated from large arteries. The present study used mouse mesenteric resistance arteries (MRAs) to investigate the role of EGFR transactivation under pressure-induced myogenic tone (MT). METHODS AND RESULTS: Isolated MRAs were mounted in an arteriograph and stimulated by 25 to 125 mm Hg or with Ang II and KCl. Stepwise increases in pressure resulted in MT development associated with increased EGFR phosphorylation and release of heparin-binding EGF (HB-EGF), a membrane-bound growth factor that is shed on cleavage by metalloproteinases. EGF (50 ng/mL) potentiated MT (59+/-1% to 51+/-0.6% of passive diameter at 75 mm Hg). Pretreatment with the EGFR inhibitors AG1478 (5 micromol/L) or PD153035 (1 micromol/L) significantly decreased MT. However, EGFR inhibitors had no effect on Ang II- and KCl-induced contraction. MT was potentiated by HB-EGF, 50 ng/mL, which is bound to the cell membrane and released on cleavage by metalloproteinases. Neutralizing HB-EGF antibodies or heparin treatment to sequester HB-EGF resulted in significant inhibition of pressure-induced MT. MT increased matrix metalloproteinase (MMP) 2 and MMP-9 gelatinase activity assessed by zymography, and specific MMP 2/9 inhibitors significantly decreased MT. CONCLUSIONS: These novel findings suggest that the mechanism of pressure-induced MT involves metalloproteinases 2/9 activation with subsequent HB-EGF release and EGFR transactivation.
Authors:
Pamela A Lucchesi; Abdelkarim Sabri; Souad Belmadani; Khalid Matrougui
Related Documents :
8384645 - Angiotensin ii and sympathetic activity in patients with congestive heart failure.
8315515 - Slow developing pressor effect of angiotensin ii and vascular structure.
11303065 - Regional vascular selectivity of angiotensin ii.
686905 - Angiotensin ii blockade in congestive heart failure.
8135435 - Trendelenburg position and oxygen transport in hypovolemic adults.
7571385 - Long-term results of complete and partial ligation of congenital portosystemic shunts i...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2004-11-22
Journal Detail:
Title:  Circulation     Volume:  110     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-07     Completed Date:  2005-06-03     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3587-93     Citation Subset:  AIM; IM    
Affiliation:
Department of Pharmacology, Louisiana State University Health Sciences Center, New Orleans, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / pharmacology
Animals
Epidermal Growth Factor / metabolism
Intercellular Signaling Peptides and Proteins
Matrix Metalloproteinase 2 / antagonists & inhibitors,  metabolism*
Matrix Metalloproteinase 9 / antagonists & inhibitors,  metabolism*
Mesenteric Arteries / physiology*
Mice
Mice, Inbred C57BL
Muscle Contraction
Muscle Tonus / physiology*
Muscle, Smooth, Vascular / physiology*
Phosphorylation
Potassium Chloride / pharmacology
Pressure
Receptor, Epidermal Growth Factor / antagonists & inhibitors,  metabolism*
Transcriptional Activation
Vascular Resistance*
Grant Support
ID/Acronym/Agency:
R01-HL-56046/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Intercellular Signaling Peptides and Proteins; 11128-99-7/Angiotensin II; 149176-25-0/heparin-binding EGF-like growth factor; 62229-50-9/Epidermal Growth Factor; 7447-40-7/Potassium Chloride; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 3.4.24.24/Matrix Metalloproteinase 2; EC 3.4.24.35/Matrix Metalloproteinase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Control of plasma nitric oxide bioactivity by perfluorocarbons: physiological mechanisms and clinica...
Next Document:  Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.